{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:24:15Z","timestamp":1795209855474,"version":"4.10.3"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Despite substantial improvements in survival over recent decades, multiple myeloma (MM) remains largely incurable, and most patients ultimately experience relapsed or refractory disease, highlighting the need for novel therapeutic strategies. Immunomodulatory drugs (IMiDs) have transformed MM treatment through direct antitumor and immune-enhancing effects mediated by cereblon modulation, while their ability to stimulate T-cell and NK-cell function has provided a strong rationale for combination with modern immunotherapies, including bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. More recently, cereblon E3 ligase modulators (CELMoDs), such as iberdomide and mezigdomide, have emerged as next-generation cereblon-targeting agents with enhanced potency, deeper substrate degradation, and activity in lenalidomide- and pomalidomide-resistant settings. Clinical studies have demonstrated promising efficacy and manageable safety profiles across newly diagnosed and relapsed\/refractory MM, including in heavily pretreated patients. In parallel, novel degraders such as cemsidomide have shown encouraging preliminary activity, further expanding the therapeutic potential of cereblon-directed approaches in MM. In this review, we aim to summarize the evolution of oral therapies in MM, focusing on the efficacy and safety of next-generation cereblon modulators and emerging cereblon-directed degraders.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000851","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:00:47Z","timestamp":1790366447000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Immunomodulatory Drugs: Next-Generation Cereblon Modulators in Multiple Myeloma"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0945-0144","authenticated-orcid":false,"given":"Lorenzo","family":"Cani","sequence":"first","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences, Division of Hematology, AOU Citta\u0300 della Salute e della Scienza di Torino, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20261120","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.3390\/cancers14235759","article-title":"Immunomodulatory agents for multiple myeloma","volume":"14","author":"Mina\u0159\u00edk","year":"2022","journal-title":"Cancers"},{"key":"R2-20261120","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jjco\/hyz083","article-title":"Immunomodulatory drugs in the treatment of multiple myeloma","volume":"49","author":"Abe","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"R3-20261120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"R4-20261120","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"R5-20261120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cellimm.2004.09.003","article-title":"Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-\u03b1, IL-1\u03b2, and LPS-stimulated human PBMC in a partially IL-10-dependent manner","volume":"230","author":"Payvandi","year":"2004","journal-title":"Cell Immunol"},{"key":"R6-20261120","doi-asserted-by":"crossref","first-page":"98200","DOI":"10.18632\/oncotarget.21516","article-title":"Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28 T-cells","volume":"8","author":"Neuber","year":"2017","journal-title":"Oncotarget"},{"key":"R7-20261120","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.3389\/fimmu.2018.03171","article-title":"Immunomodulatory drugs in the context of autologous hematopoietic stem cell transplantation associate with reduced pro-tumor T cell subsets in multiple myeloma","volume":"9","author":"Di Lullo","year":"2019","journal-title":"Front Immunol"},{"key":"R8-20261120","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"key":"R9-20261120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R10-20261120","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T-cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"R11-20261120","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12967-024-05772-w","article-title":"BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed\/refractory multiple myeloma","volume":"22","author":"Yan","year":"2024","journal-title":"J Transl Med"},{"key":"R12-20261120","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"R13-20261120","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"key":"R14-20261120","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42","author":"Touzeau","year":"2024","journal-title":"JCO"},{"key":"R15-20261120","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2025.43.16_suppl.7504","article-title":"Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1","volume":"43","author":"Quach","year":"2025","journal-title":"JCO"},{"key":"R16-20261120","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1182\/blood-2024-199773","article-title":"Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in combination with daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma: safety and efficacy results from the phase 1b monumental-2 study","volume":"144","author":"Nooka","year":"2024","journal-title":"Blood"},{"key":"R17-20261120","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/blood-2022-162733","article-title":"MonumenTAL-3: phase 3 trial of talquetamab + daratumumab \u00b1 pomalidomide versus daratumumab + pomalidomide + dexamethasone in relapsed\/refractory multiple myeloma following \u22651 prior line of therapy","volume":"140","author":"Cohen","year":"2022","journal-title":"Blood"},{"key":"R18-20261120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2024-206003","article-title":"Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial","volume":"144","author":"Raab","year":"2024","journal-title":"Blood"},{"key":"R19-20261120","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/OTT.S398118","article-title":"The role of CELMoD agents in multiple myeloma","volume":"18","author":"Van De Donk","year":"2025","journal-title":"OTT"},{"key":"R20-20261120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"key":"R21-20261120","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1182\/blood-2019-124298","article-title":"Translational and clinical evidence of a differentiated profile for the novel CELMoD, iberdomide (CC-220)","volume":"134","author":"Lonial","year":"2019","journal-title":"Blood"},{"key":"R22-20261120","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"R23-20261120","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1182\/blood-2019-126146","article-title":"Multidimensional single cell analysis shows increased T\/NK cell subsets in both blood and bone marrow of iberdomide (CC-220) treated relapsed\/refractory multiple myeloma patients","volume":"134","author":"Amatangelo","year":"2019","journal-title":"Blood"},{"key":"R24-20261120","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2018-99-113383","article-title":"Iberdomide (CC-220) has synergistic anti-tumor and immunostimulatory activity against multiple myeloma in combination with both bortezomib and dexamethasone, or in combination with daratumumab in vitro","volume":"132","author":"Amatangelo","year":"2018","journal-title":"Blood"},{"key":"R25-20261120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-137667","article-title":"Preclinical and translational data support development of iberdomide in combination with CD38- and SLAMF7-directed monoclonal antibodies: evidence for rational combinations","volume":"136","author":"Amatangelo","year":"2020","journal-title":"Blood"},{"key":"R26-20261120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-137710","article-title":"Preclinical and translational support for clinical development of iberdomide in combination with proteasome inhibitors: mechanism of synergy in clinical trial CC-220-MM-001","volume":"136","author":"Amatangelo","year":"2020","journal-title":"Blood"},{"key":"R27-20261120","doi-asserted-by":"crossref","first-page":"e805462a","DOI":"10.1097\/01.HS9.0000970100.80546.2a","article-title":"P799: synergistic antitumor activity of the BCMA 2 + 1 T-cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and CELMOD agents in multiple myeloma (MM) preclinical models","volume":"7","author":"Paiva","year":"2023","journal-title":"HemaSphere"},{"key":"R28-20261120","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S2152-2650(21)02087-5","article-title":"OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"21","author":"Lonial","year":"2021","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"R29-20261120","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/14796694.2025.2501920","article-title":"EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"21","author":"Lonial","year":"2025","journal-title":"Future Oncol"},{"key":"R30-20261120","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"The Lancet Hematology"},{"key":"R31-20261120","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/blood-2022-158180","article-title":"Iberdomide (IBER) in combination with dexamethasone (DEX) in relapsed\/refractory multiple myeloma (RRMM): results from the anti-B-cell maturation antigen (BCMA)-exposed cohort of the CC-220-MM-001 trial","volume":"140","author":"Lonial","year":"2022","journal-title":"Blood"},{"key":"R32-20261120","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1200\/JCO.2026.44.16_suppl.7514","article-title":"Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma","volume":"44","author":"Kapoor","year":"2026","journal-title":"J Clin Oncol"},{"key":"R33-20261120","doi-asserted-by":"crossref","first-page":"S897","DOI":"10.1016\/S2152-2650(25)02560-1","article-title":"MM-101: iberdomide (IBER), daratumumab (DARA), and dexamethasone (DEX) (IberDd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): results from the phase 1\/2 CC-220-MM-001 trial","volume":"25","author":"Balari","year":"2025","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"R34-20261120","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1182\/blood-2025-5810","article-title":"Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial","volume":"146","author":"Sureda Balar\u00ed","year":"2025","journal-title":"Blood"},{"key":"R35-20261120","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1016\/S2152-2650(22)00609-7","article-title":"P-279: efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial","volume":"22","author":"Van De Donk","year":"2022","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"R36-20261120","first-page":"12","article-title":"Iberdomide, bortezomib, and dexamethasone (IBERVD) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): updated results from the CC-220-MM-001 trial","author":"White","year":"2025","journal-title":"Presented at EHA"},{"key":"R37-20261120","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/bjh.19978","article-title":"Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse","volume":"206","author":"Touzeau","year":"2025","journal-title":"Br J Haematol"},{"key":"R38-20261120","doi-asserted-by":"crossref","first-page":"S363","DOI":"10.1016\/S2152-2650(25)04006-6","article-title":"Efficacy and safety of iberdomide, daratumumab, and dexamethasone, in transplant-ineligible newly diagnosed multiple myeloma patients: initial analysis of the GEM-IBERDARAX trial","volume":"25","author":"Gonz\u00e1lez-Calle","year":"2025","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"R39-20261120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2025-101","article-title":"Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: an update from the phase 2 EMN26 trial","volume":"146","author":"Van De Donk","year":"2025","journal-title":"Blood"},{"key":"R40-20261120","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S2152-2650(23)01755-X","article-title":"P-137 A phase 3, two-stage, randomized study of iberdomide maintenance versus lenalidomide maintenance post autologous stem cell transplantation in newly diagnosed multiple myeloma: EXCALIBER-maintenance","volume":"23","author":"Gay","year":"2023","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"R41-20261120","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2025-100","article-title":"Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial","volume":"146","author":"Suvannasankha","year":"2025","journal-title":"Blood"},{"key":"R42-20261120","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S2352-3026(25)00298-4","article-title":"Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial","volume":"13","author":"Korst","year":"2026","journal-title":"The Lancet Hematology"},{"key":"R43-20261120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2025-251","article-title":"A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed\/refractory multiple myeloma: the rekindle study","volume":"146","author":"Landgren","year":"2025","journal-title":"Blood"},{"key":"R44-20261120","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1182\/blood-2025-5841","article-title":"An immune-therapeutic salvage strategy for \u2018functional\u2019 high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone-the IBIS study amarc 20-01","volume":"146","author":"Lim","year":"2025","journal-title":"Blood"},{"key":"R45-20261120","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1182\/blood-2025-249","article-title":"Interim analysis of efficacy and safety for ALLG MM25 (Viber-M): A phase I b\/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11;14)","volume":"146","author":"Sim","year":"2025","journal-title":"Blood"},{"key":"R46-20261120","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"key":"R47-20261120","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2024-198408","article-title":"Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated results from the CC-92480-MM-002 trial","volume":"144","author":"Sandhu","year":"2024","journal-title":"Blood"},{"key":"R48-20261120","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2023-174443","article-title":"Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 Trial","volume":"142","author":"Richardson","year":"2023","journal-title":"Blood"},{"key":"R49-20261120","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2024-198403","article-title":"Mezigdomide (MEZI) in novel-novel combinations for relapsed or refractory multiple myeloma (RRMM): preliminary results from the CA057-003 trial","volume":"144","author":"Costa","year":"2024","journal-title":"Blood"},{"key":"R50-20261120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA7506","article-title":"Mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed\/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial","volume":"44","author":"Richardson","year":"2026","journal-title":"J Clin Oncol"},{"key":"R51-20261120","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/S2152-2650(23)01446-5","article-title":"MM-372 a phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed\/refractory multiple myeloma (RRMM): SUCCESSOR-1","volume":"23","author":"Richardson","year":"2023","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"R59-20261120","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1200\/JCO.2026.44.16_suppl.7528","article-title":"Iberdomide (Iber) maintenance following upfront autologous stem cell transplant (ASCT) in multiple myeloma (MM)","volume":"44","author":"Wildes","year":"2026","journal-title":"J Clin Oncol"},{"key":"R62-20261120","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1182\/blood-2024-211651","article-title":"Elotuzumab-iberdomide-dexamethasone combination therapy activates T and NK cells within the immune microenvironment of multiple myeloma patients","volume":"144","author":"Chen","year":"2024","journal-title":"Blood"},{"key":"R65-20261120","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMe2307370","article-title":"Mezigdomide and multiple myeloma","volume":"389","author":"Shortt","year":"2023","journal-title":"N Engl J Med"},{"key":"R66-20261120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"key":"R67-20261120","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/blood-2019-124338","article-title":"CC-92480 is a novel cereblon E3 ligase modulator with enhanced tumoricidal and immunomodulatory activity against sensitive and resistant multiple myeloma cells","volume":"134","author":"Lopez-Girona","year":"2019","journal-title":"Blood"},{"key":"R68-20261120","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2023-187748","article-title":"Mezigdomide treatment in relapsed-refractory myeloma patients shifts bone marrow NK and T-cell populations from exhaustion to activation","volume":"142","author":"Chen","year":"2023","journal-title":"Blood"},{"key":"R69-20261120","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2019-124345","article-title":"CC-92480, a novel cereblon E3 ligase modulator, is synergistic with dexamethasone, bortezomib, and daratumumab in multiple myeloma","volume":"134","author":"Wong","year":"2019","journal-title":"Blood"},{"key":"R70-20261120","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1182\/blood-2022-157987","article-title":"Synergistic antitumor activity of alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T Cell Engager (TCE), and celmod agents in multiple myeloma (MM) preclinical models","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"R71-20261120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40364-025-00825-8","article-title":"Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma","volume":"13","author":"Kegyes","year":"2025","journal-title":"Biomark Res"},{"key":"R72-20261120","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/blood-2025-5835","article-title":"Phase I\/II study of mezigdomide and elranatamab for relapsed\/refractory multiple myeloma patients (MELT-MM): Initial results from part 1","volume":"146","author":"Byun","year":"2025","journal-title":"Blood"},{"key":"R75-20261120","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1182\/blood-2025-5807","article-title":"Trial in progress: a phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"146","author":"Bal","year":"2025","journal-title":"Blood"},{"key":"R78-20261120","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood-2024-204255","article-title":"Initial results of a phase 1 first-in-human study of cemsidomide (CFT7455), a novel MonoDACTM degrader, with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"},{"key":"R80-20261120","doi-asserted-by":"crossref","first-page":"S2152265026000674","DOI":"10.1016\/j.clml.2026.03.003","article-title":"The evolution of chimeric antigen receptor T-Cell, bispecific antibodies and antibody-drug conjugates for the treatment of multiple myeloma","volume":"26","author":"Cani","year":"2026","journal-title":"Clinical Lymphoma Myeloma and Leukemia"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:00:17Z","timestamp":1795208417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000851","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-06-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}